WEX Goes to Court: HP Sued for Alleged Trademark Misuse
WEX Inc. files federal lawsuit against HP for infringing trademarks with their HP Wex product, causing confusion in the marketplace.
Did UnitedHealth Execs Break Security Laws? Company Faces Scrutiny Over Executives’ Stock Sales Amid Antitrust Probe
Reports reveal UnitedHealth executives profited $101.5 million from stock sales ahead of a DOJ antitrust inquiry announcement. Speculation surrounds the timing and approval of these trades amid ongoing investigations.
Deckers Outdoor Faces Direct-To-Consumer Growth Slowdown, Analyst Downgrades Stock
Analyst lowers rating on DECK and price target due to weaker DTC growth. EPS estimates also reduced for FY24-26.
Black Gold Bonanza: Analyst Bets On Chevron, Citing Price Outlook
Analyst remains optimistic that Chevron will prevail in the arbitration against Exxon Mobil and CNOOC in Guyana.
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government stalled despite incentives.
Nike Bets On Olympics to Boost Performance Sales: Report
NIKE shares rise as it launches Olympic kits for sponsored teams & athletes. BofA upgrades stock with $113 price target.
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024.
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA approvals signal growth.
Vertex Pharmaceutical’s Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.
Legal Battle Over Enbridge Pipeline: Biden Administration Reportedly Urges Review
Biden admin urges appeals court to reconsider order for Enbridge to drain part of pipeline on tribal land, citing treaty violation.